Last $10.55 USD
Change Today -0.02 / -0.19%
Volume 60.9K
ICAD On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

icad inc (ICAD) Snapshot

Open
$10.58
Previous Close
$10.57
Day High
$10.63
Day Low
$10.44
52 Week High
01/16/14 - $14.11
52 Week Low
10/1/13 - $5.16
Market Cap
162.9M
Average Volume 10 Days
79.1K
EPS TTM
$-0.46
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICAD INC (ICAD)

Related News

No related news articles were found.

icad inc (ICAD) Related Businessweek News

No Related Businessweek News Found

icad inc (ICAD) Details

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. The company operates in two segments, Cancer Detection and Cancer Therapy. It offers electronic brachytherapy products (eBx), including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, and non-melanoma skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated, including intraoperative radiation therapy. The company also provides digital and magnetic resonance imaging (MRI) computer-aided detection (CAD) products, such as SecondLook systems that detect and identify suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer’s network that receives patient studies from the imaging modality, performs CAD analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, it offers advanced image analysis and workflow solutions in MRI imaging; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. Further, the company provides film based products, such as TotalLook MammoAdvantage system, which is a second generation mammography specific digitizer that converts prior mammography films to digital images. iCAD, Inc. primarily serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses. The company sells its products directly, as well as through various original equipment manufacturer partners, distributors, and resellers worldwide. It has strategic partnership agreement with Invivo Corporation. The company was founded in 1984 and is headquartered in Nashua, New Hampshire.

102 Employees
Last Reported Date: 03/3/14
Founded in 1984

icad inc (ICAD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $412.4K
Chief Operating Officer
Total Annual Compensation: $328.6K
Senior Vice President of Marketing and Strate...
Total Annual Compensation: $253.6K
Compensation as of Fiscal Year 2013.

icad inc (ICAD) Key Developments

iCAD, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Second Half of 2014

iCAD, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, net loss and comprehensive loss was $997,000, or $0.07 per basic and diluted common unit, on total revenue of $9,667,000 compared to net loss and comprehensive loss was $1,872,000, or $0.17 per basic and diluted common unit, on total revenue of $7,712,000 a year ago. Loss from operations was $166,000 compared to $473,000 a year ago. Loss before income tax expense was $972,000 compared to $1,872,000 a year ago. Non GAAP adjusted EBITDA was $917,000 compared to $434,000 a year ago. Non GAAP adjusted net loss was $589,000, or $0.04 per share compared to Non GAAP adjusted net loss was $1,311,000, or $0.12 per share For the six months, net loss and comprehensive loss was $1,187,000, or $0.09 per basic and diluted common unit, on total revenue of $18,187,000 compared to net loss and comprehensive loss was $2,609,000, or $0.24 per basic and diluted common unit, on total revenue of $15,642,000 a year ago. Loss from operations was $626,000 compared to $801,000 a year ago. Loss before income tax expense was $1,109,000 compared to $2,589,000 a year ago. Net cash used for operating activities was $2,336,000 compared to $721,000 a year ago. Additions to patents, technology and other were $44,000 compared to $19,000 a year ago. Additions to property and equipment were $465,000 compared to $274,000 a year ago. Non GAAP adjusted EBITDA was $1,364,000 compared to $1,026,000 a year ago. Non GAAP adjusted net loss was $1,915,000, or $0.15 per share compared to Non GAAP adjusted net loss was $2,469,000, or $0.23 per share a year ago. The company introduced financial guidance for the second half of 2014, with the company expecting total revenue to be in the range of $23 million to $25 million. The company also expects to achieve adjusted EBITDA margins in the range of 10% to 15% during the second half of 2014.

iCAD, Inc. to Report Q2, 2014 Results on Jul 30, 2014

iCAD, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 30, 2014

iCAD, Inc., Q2 2014 Earnings Call, Jul 30, 2014

iCAD, Inc., Q2 2014 Earnings Call, Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $10.55 USD -0.02

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $24.87 USD +0.16
Merge Healthcare Inc $2.60 USD +0.02
View Industry Companies
 

Industry Analysis

ICAD

Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit www.icadmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.